These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22710893)

  • 1. Hematopoietic cell transplantation for B-cell lymphoma: an update.
    Ayala E
    Cancer Control; 2012 Jul; 19(3):175-86. PubMed ID: 22710893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic cell transplantation for lymphomas.
    Ayala E; Tomblyn M
    Cancer Control; 2011 Oct; 18(4):246-57. PubMed ID: 21976243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).
    Papageorgiou SG; Cwynarski K; Kottaridis PD
    Bone Marrow Transplant; 2013 Oct; 48(10):1271-8. PubMed ID: 23318539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
    Dreger P; Laport GG
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
    Fenske TS; Hamadani M; Cohen JB; Costa LJ; Kahl BS; Evens AM; Hamlin PA; Lazarus HM; Petersdorf E; Bredeson C
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1543-1551. PubMed ID: 27131863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
    Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.
    Epperla N; Hamadani M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress: hematopoietic cell transplant for diffuse large B-cell lymphoma.
    Farooq U; Laport GG
    Leuk Lymphoma; 2015 Jul; 56(7):1930-7. PubMed ID: 25315072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.
    Rezvani AR; Kanate AS; Efron B; Chhabra S; Kohrt HE; Shizuru JA; Laport GG; Miklos DB; Benjamin JE; Johnston LJ; Arai S; Weng WK; Negrin RS; Strober S; Lowsky R
    Bone Marrow Transplant; 2015 Oct; 50(10):1286-92. PubMed ID: 26146806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?
    Kharfan-Dabaja MA; El-Jurdi N; Ayala E; Kanate AS; Savani BN; Hamadani M
    Bone Marrow Transplant; 2017 Nov; 52(11):1487-1494. PubMed ID: 28368373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation for non-Hodgkin lymphoma.
    Nademanee A
    Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?
    Hamadani M
    Bone Marrow Transplant; 2013 Aug; 48(8):1013-21. PubMed ID: 23000653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
    Bethge WA; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
    Bone Marrow Transplant; 2012 Nov; 47(11):1397-402. PubMed ID: 22504934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts.
    Uhm J; Kuruvilla J
    Transfus Apher Sci; 2013 Aug; 49(1):63-71. PubMed ID: 23790650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
    Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
    Atilla E; Atilla PA; Demirer T
    Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.